Market Overview

Barclays Analyst Pens Open Letter To Gilead Board And Management

Share:
Barclays Analyst Pens Open Letter To Gilead Board And Management
Related GILD
ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More
Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher
Gilead Sciences - The Silver Bullet For NASH With Selonsertib And GS-9674 Combinations Treatment (Seeking Alpha)

On Friday, Barclays analyst Geoff Meacham veered from his typical approach of addressing clients and chose to speak directly to management at Gilead Sciences, Inc. (NASDAQ: GILD). Meacham chose to structure his latest research note on the pharma giant as a letter to the company, which included five recommendations for ways the company could potentially boost its market valuation.

According to Meacham, market sentiment toward Gilead seems to be at a low point recently.

“The purpose of this letter isn’t to single out your company as one that has been mismanaged (it hasn’t); rather, it is to provide context for the current valuation and with five concluding recommendations, help carve a roadmap to a re-rating,” Meacham explained.

5-Step Process

Barclays believes Gilead management can be proactive by taking the following five steps:

    1. Consider transformational M&A deals outside of the company’s core businesses.
    2. Consider cutting costs in the hepatitis C business if the market continues to decline.
    3. Give more clarity on the potential impact of the HIV franchise by providing guidance.
    4. Consider taking a more aggressive approach to in-licensing/business development.
    5. Consider shifting focus away from capital return and more toward reinvesting in the business via M&A and other potential growth measures.

Like most pharma stocks, Gilead has had a rough go of it in the past year, with shares now down 21.9 percent.

Barclays remains optimistic, however. The firm maintains an Outperform rating and a $90 price target for the stock.

Related Link:

  • Here's Who's Getting A Tax Cut Under The New Healthcare Proposal (You're Probably Not Included)
  • Response To GOP Healthcare Bill Ranges From Tepid Support To Outright Opposition
  • Latest Ratings for GILD

    DateFirmActionFromTo
    Nov 2017Maxim GroupUpgradesHoldBuy
    Nov 2017ArgusDowngradesBuyHold
    Oct 2017BMO CapitalMaintainsOutperform

    View More Analyst Ratings for GILD
    View the Latest Analyst Ratings

    Posted-In: Analyst Color Biotech Long Ideas Health Care Politics Analyst Ratings Movers Trading Ideas Best of Benzinga

     

    Related Articles (GILD)

    View Comments and Join the Discussion!